Abstract | PURPOSE: The National Wilms' Tumor Study (NWTS)-4 was designed to evaluate the efficacy, toxicity, and cost of administration of different regimens for the treatment of Wilms' tumor (WT). PATIENTS AND METHODS: Between August 6, 1986 and September 1, 1994, 1,687 previously untreated children less than 16 years of age with stages I to II/favorable histology (FH) or stage I/anaplastic histology WT (low-risk [LR] group) or stages III to IV/FH WT or stages I to IV/ clear cell sarcoma of the kidney (high-risk [HR] group) were randomized to treatment that included vincristine and either divided-dose (standard [STD]) courses (5 days) or single-dose (pulse-intensive [PI]) treatment with dactinomycin. HR patients also received either STD courses (3 days) or PI treatment with doxorubicin. RESULTS: The 2-year relapse-free survival (RFS) rates for LR patients were 91.3% for 544 randomized to treatment with PI and 91.4% for 556 randomized to treatment with STD chemotherapy (P = .988). The 2-year RFS rates for HR patients were 87.3% for 299 randomized to treatment with PI and 90.0% for 288 randomized to treatment with STD chemotherapy (P = .865). CONCLUSION: We conclude that patients treated with PI combination chemotherapy for LR or HR WT or clear cell sarcoma of the kidney have equivalent 2-year RFS to those treated with STD regimens. PI drug administration is recommended as the new standard based on demonstrated efficacy, greater administered dose-intensity, less severe hematologic toxicity, and the requirement for fewer physician and hospital encounters.
|
Authors | D M Green, N E Breslow, J B Beckwith, J Z Finklestein, P E Grundy, P R Thomas, T Kim, S J Shochat, G M Haase, M L Ritchey, P P Kelalis, G J D'Angio |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 16
Issue 1
Pg. 237-45
(Jan 1998)
ISSN: 0732-183X [Print] United States |
PMID | 9440748
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Dactinomycin
- Vincristine
- Doxorubicin
|
Topics |
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Child
- Child, Preschool
- Combined Modality Therapy
- Dactinomycin
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Humans
- Infant
- Kidney Neoplasms
(drug therapy, pathology, radiotherapy, surgery)
- Lung Diseases, Interstitial
(etiology)
- Neoplasm Staging
- Neoplasms, Germ Cell and Embryonal
(drug therapy, pathology, radiotherapy, surgery)
- Nephrectomy
- Vincristine
(administration & dosage, adverse effects)
- Wilms Tumor
(drug therapy, pathology, radiotherapy, surgery)
|